Accession Number:



A New Paradigm for the Treatment of Ovarian Cancer: The Use of Epigenetic Therapy to Sensitize Patients to Immunotherapy and Chemotherapy

Descriptive Note:

Technical Report,30 Sep 2017,29 Sep 2018

Corporate Author:

The Johns Hopkins University Baltimore United States

Personal Author(s):

Report Date:


Pagination or Media Count:



Our overall goal remains to bring epigenetic therapy to have major impact for the management of advanced ovarian cancer OC. This past year, we continue to make exciting advances in our pre-clinical work and interim results from our leveraged clinical trial is pending now for low dose therapy targeting DNA demethylation paired with immune checkpoint therapy. Our two relevant studies of mouse models are now published, a study of aserous ovarian cancer in which we have identified that the demethylating agent, 5-aza-cytidine AZA potently stimulates tumor immune attraction of T-cells to the tumor microenvironment PNAS, 2017. The treatment paradigm involves a newly regimen we first derived for addition of a histone deactylase inhibitor HDACi in a study of mouse models for lung cancer Cell, 2017. Further, we have just published work showing how an inhibitor of G9A, an enzyme mediating transcriptional repression, can augment the above AZA effects to induce the immune attraction parameters in OC cells Cancer Research, 2018. All of the above findings continue to document how epigenetic therapy can potentially improve immune checkpoint therapy for OC.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement: